Hengehold Capital Management LLC Buys 147 Shares of STERIS plc (NYSE:STE)

Hengehold Capital Management LLC grew its stake in STERIS plc (NYSE:STE) by 15.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,078 shares of the medical equipment provider’s stock after acquiring an additional 147 shares during the quarter. Hengehold Capital Management LLC’s holdings in STERIS were worth $261,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Central Pacific Bank Trust Division bought a new position in STERIS in the 3rd quarter worth about $28,000. J.Safra Asset Management Corp lifted its stake in shares of STERIS by 77.9% in the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 53 shares in the last quarter. Quent Capital LLC grew its holdings in shares of STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 71 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of STERIS during the first quarter valued at approximately $36,000. Finally, Versant Capital Management Inc raised its holdings in STERIS by 2,262.5% in the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 181 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Stock Down 0.4 %

Shares of STE stock opened at $225.00 on Friday. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. STERIS plc has a 12 month low of $195.47 and a 12 month high of $248.24. The stock has a market cap of $22.19 billion, a P/E ratio of 55.83 and a beta of 0.84. The company has a 50 day simple moving average of $235.86 and a two-hundred day simple moving average of $225.91.

STERIS (NYSE:STE) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. The company had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. STERIS’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period last year, the firm earned $2.00 EPS. On average, research analysts expect that STERIS plc will post 9.06 earnings per share for the current year.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were given a dividend of $0.57 per share. This is a boost from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date was Thursday, September 5th. STERIS’s payout ratio is presently 56.58%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on STE shares. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research note on Wednesday, August 7th. StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. Stephens reaffirmed an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Finally, KeyCorp boosted their target price on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and an average target price of $246.00.

Insider Activity at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the transaction, the director now directly owns 582 shares of the company’s stock, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.